{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/herpes-simplex-genital/management/recurrent-episode/","result":{"pageContext":{"chapter":{"id":"6fabaee2-7d86-57a7-955e-be56c41f79bb","slug":"recurrent-episode","fullItemName":"Scenario: Recurrent episode","depth":2,"htmlHeader":"<!-- begin field bcacc282-6de4-4d06-b7cb-a75100d4ec65 --><h2>Scenario: Recurrent episode</h2><!-- end field bcacc282-6de4-4d06-b7cb-a75100d4ec65 -->","summary":"Covers the assessment and management in primary care of recurrent episodes of genital herpes.","htmlStringContent":"<!-- begin item ba4adc91-d0ea-4a85-91f8-a75100d4ed39 --><!-- begin field 3d414396-db8c-449a-bc29-acbd008896c8 --><p>From age 13 years onwards.</p><!-- end field 3d414396-db8c-449a-bc29-acbd008896c8 --><!-- end item ba4adc91-d0ea-4a85-91f8-a75100d4ed39 -->","topic":{"id":"ea9192a7-1cda-514b-8960-509d26282765","topicId":"501ea0cd-acdf-4cd7-bab7-e2043816027a","topicName":"Herpes simplex - genital","slug":"herpes-simplex-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"be649b3f-aab9-5c90-ba68-206ff0cb4be4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5247b7c3-3bd5-5827-8952-92575d834222","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f9e89c8b-9d32-562e-a793-d3d0472a139f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2fa3fae0-6a76-541b-8497-33471312a0b3","slug":"changes","fullItemName":"Changes"},{"id":"752dc01e-c669-5f0f-a6a5-8135e6adba24","slug":"update","fullItemName":"Update"}]},{"id":"b876d783-2ea3-56c8-b9b7-058854ee57ea","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d3f87500-c2da-56cd-9c46-4428e771b599","slug":"goals","fullItemName":"Goals"},{"id":"0c2f0fcc-325f-5e09-8536-f60c309bce01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dafa3441-13e9-5b23-8021-3a3ea3ba5f00","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c7885774-245f-5356-bbf0-70a37d6ca3f7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b6bcebe1-8904-53aa-b5d9-1754be58022e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e662dba3-03df-56c1-8cb2-d71bbba36816","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8cdad5a8-4a0a-57c0-971d-f2c81f600f55","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dd0dddfb-f2c0-5751-83c7-775739a083ee","slug":"definition","fullItemName":"Definition"},{"id":"248932d1-b0c9-5f9a-964a-1b1e6a4dde7f","slug":"causes","fullItemName":"Causes"},{"id":"e76b4902-cd2c-587d-a48d-dd59fcfc6dd2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"afd4e2b6-2ac2-5163-8ffc-e5a8a613b237","slug":"transmission","fullItemName":"Transmission"},{"id":"029f6c38-010b-500d-ba38-1bfc65b68785","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1bc7ca7-6937-53a2-81ad-53db850f43e6","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"4b35cac6-8364-5a89-af85-9a530ac9c623","slug":"complications","fullItemName":"Complications"},{"id":"220b9c2f-04f4-5101-a56f-6fa09b02c420","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ac23dddb-072b-5c43-8b04-c85a674d3d5a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9d1e89ed-323b-5959-9318-c170832a29d0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"29beab39-2c1c-518d-a77e-9cd3b9776cad","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee065d2-c568-5cf5-9f2e-0cbe67416849","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"4f2bc977-086e-5488-ab30-c8dea7c697a6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"779875c0-dc12-576e-bc57-c01d56c3b980","fullItemName":"Management","slug":"management","subChapters":[{"id":"6a765e6a-67a6-5ad9-a9da-9d4eb4d0b5ce","slug":"first-episode","fullItemName":"Scenario: First episode"},{"id":"6fabaee2-7d86-57a7-955e-be56c41f79bb","slug":"recurrent-episode","fullItemName":"Scenario: Recurrent episode"}]},{"id":"8471b333-320c-5216-bc84-578c843fbc84","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"333339e9-bc78-586f-b4a6-e65109ceb357","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b08eed31-5709-5683-9ad7-7e076ebea12d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d3573af7-fe16-5a8f-91e6-a899683376bc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cf9761b1-f157-5815-9721-f84c01bbf1de","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"71606be4-fc8b-5e02-830c-b2b2dde16541","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17f98f15-1165-5b48-a166-f0fb5335186b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8bfdd1e1-340f-50f5-ae55-79e66b213886","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"779875c0-dc12-576e-bc57-c01d56c3b980","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"185d4708-c7ec-5d42-bc03-44758536a99f","slug":"assessment","fullItemName":"Assessment","depth":3,"htmlHeader":"<!-- begin field 911d35fa-34f2-4978-81cc-a75100d4ec6a --><h3>How should I assess someone with recurrent genital herpes?</h3><!-- end field 911d35fa-34f2-4978-81cc-a75100d4ec6a -->","summary":null,"htmlStringContent":"<!-- begin item 5792942e-5b5e-43be-a5f7-a75100d4ec6a --><!-- begin field 630e46aa-9454-41c4-a248-a75100d4ec6a --><ul><li>Ask how the diagnosis of genital herpes was confirmed and when — ideally, it should be diagnosed by a specialist in genito-urinary medicine and the herpes simplex virus identified by positive viral culture or polymerase chain reaction (PCR).</li><li>Ask about the <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/diagnosis/signs-symptoms/\">signs and symptoms</a>, whether lesions are still forming, their onset (determine if started within 5 days), and whether the person experiences prodromal sensations (tingling or burning).<ul><li>Symptoms are usually milder, lesions appear in a smaller area, and heal more quickly than the initial episode. </li></ul></li><li>Ask about the previous attacks:<ul><li>How recently they occurred (within the last year).</li><li>Frequency and severity (usually decreasing with time).</li><li>Duration (the initial episode can last for up to 20 days, while recurrent attacks usually last 5–10 days).</li><li>Management (self-care and/or antiviral medication).</li></ul></li><li>Ask whether the person has identified personal <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/background-information/trigger-factors/\">trigger factors</a> (for example sexual intercourse, sunlight).</li><li>Examine the external genitalia and surrounding skin — lesions are usually unilateral (initial episodes are bilateral) and localized to the same area in each attack.</li><li>Determine the person's understanding of genital herpes (causes, prognosis, risk of transmission) and enquire (if appropriate) about the affect on self-esteem, mood, and relationships. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#advice\">Advice</a>.</li></ul><!-- end field 630e46aa-9454-41c4-a248-a75100d4ec6a --><!-- end item 5792942e-5b5e-43be-a5f7-a75100d4ec6a -->","subChapters":[{"id":"2e9a4c03-c946-520f-9aa0-3c8d5cf127c0","slug":"basis-for-recommendation-6a5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7234b694-bb1f-4d41-afd7-a75100d4ec6f --><h4>Basis for recommendation</h4><!-- end field 7234b694-bb1f-4d41-afd7-a75100d4ec6f -->","summary":null,"htmlStringContent":"<!-- begin item 6a5fbddd-3c75-4b12-9de3-a75100d4ec6f --><!-- begin field 5c928a76-8fa1-421e-851c-a75100d4ec6f --><p>CKS found no national guidelines for assessing the recurrence of genital herpes simplex. These recommendations are largely based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of anogenital herpes </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the British Medical Journal (BMJ) best practice guide <em>Herpes simplex infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BMJ Best Practice, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>], expert opinion in a narrative review <em>Genital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Gnann, 2016</a>], and what CKS consider good clinical practice.</p><h5>Confirming the diagnosis</h5><ul><li>In people with a previously laboratory-confirmed diagnosis, the clinical history is often the principal means of determining that the person has a recurrent episode [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].<ul><li>While clinical examination alone is unable to reliably distinguish between a first episode, or recurrence, presence of a prodrome suggests recurrence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Gnann, 2016</a>].</li></ul></li></ul><!-- end field 5c928a76-8fa1-421e-851c-a75100d4ec6f --><!-- end item 6a5fbddd-3c75-4b12-9de3-a75100d4ec6f -->","subChapters":[]}]},{"id":"fef67b7b-7a08-5574-87fb-91163bd7808d","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 276565d1-1989-4e52-b376-a75100d6a204 --><h3>How should I treat someone with recurrent genital herpes?</h3><!-- end field 276565d1-1989-4e52-b376-a75100d6a204 -->","summary":null,"htmlStringContent":"<!-- begin item b3150fdc-e146-44d9-b512-a75100d6a2aa --><!-- begin field 4fceedf3-b4bb-4f0f-bc6c-a75100d6a204 --><ul><li>Self-care measures may be helpful for some people. For more information see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#self-care-measures\">self care</a>.</li><li>If self-care measures are not controlling symptoms, management decisions should be made in partnership with the person. Options include:<ul><li>Episodic antiviral treatment — if attacks are infrequent (less than six attacks per year).<ul><li>Prescribe oral aciclovir 800 mg three times a day for 2 days, famciclovir 1000 mg twice a day for 1 day, or valaciclovir 500 mg twice a day for 3 days.</li><li>Alternatively, for 5-day treatment regimens: prescribe aciclovir 200 mg five times a day (or 400 mg three times a day) valaciclovir 500 mg twice a day, or famciclovir 125-250 mg twice a day.</li><li>Consider self-initiated treatment, so antiviral medication can be started early in the next attack.</li></ul></li><li>Suppressive antiviral treatment — if attacks are frequent (six or more attacks per year), causing psychological distress, or affecting the person's social life. <ul><li>Prescribe aciclovir 400 mg twice a day (or 200 mg four times a day), famciclovir 250 mg twice a day, or valaciclovir 500 mg once a day.</li><li>If breakthrough recurrences occur, the dosage should be increased. Consider seeking specialist advice.</li><li>Continue treatment for a maximum of one year, after which it should be stopped to assess recurrence (for a minimum of two recurrences). Consider restarting treatment in people who have high rates of recurrence. </li></ul></li></ul></li><li>The best strategy may change over time according to recurrence frequency, symptom severity, and relationship status.</li></ul><!-- end field 4fceedf3-b4bb-4f0f-bc6c-a75100d6a204 --><!-- end item b3150fdc-e146-44d9-b512-a75100d6a2aa -->","subChapters":[{"id":"33e9e9e6-6039-5b46-944f-a6b478f1bef9","slug":"basis-for-recommendation-aa3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 10a8b566-805b-419e-90a1-a75100d6a208 --><h4>Basis for recommendation</h4><!-- end field 10a8b566-805b-419e-90a1-a75100d6a208 -->","summary":null,"htmlStringContent":"<!-- begin item aa321008-d10f-4eb7-b339-a75100d6a208 --><!-- begin field f54211b4-59f0-4c80-afb9-a75100d6a208 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of genital herpes </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], and a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>] and the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>].</p><p><strong>Self-initiated treatment </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]</p><ul><li>Treatment started early in an episode is most likely to be effective, as treatment prior to the development of papules is of greatest benefit.</li><li>Aborted lesions have been documented in up to one-third of people with early treatment.</li></ul><p><strong>Suppressive therapy </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>]</p><ul><li>The decision to start suppressive prescribing is a subjective one, balancing the frequency of attacks against the cost and commitment of taking regular medication.</li></ul><p><strong>Choice of antiviral, dose and duration of treatment </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]</p><ul><li>Be aware that dose recommendations for antivirals and the duration of treatment may differ between guidelines for treatment of genital herpes, the Summary of Product Characteristics and the British National Formulary (BNF). <ul><li>BASHH recommends a dose of 125 mg of famciclovir twice a day, while WHO recommends 250 mg twice a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>].</li><li>CKS recommends using clinical judgment to determine the dose and duration of treatment of antiviral.</li></ul></li><li>There is no evidence to support using one antiviral over another or to show that one episodic treatment regimen is more efficacious than another. <ul><li>The decision should be made with the person, and take into account factors such as convenience of dosing frequency, and cost.</li></ul></li></ul><!-- end field f54211b4-59f0-4c80-afb9-a75100d6a208 --><!-- end item aa321008-d10f-4eb7-b339-a75100d6a208 -->","subChapters":[]}]},{"id":"cb18c2b1-33a8-5d30-ac05-12e7deacd9cc","slug":"treatment-in-someone-with-hiv","fullItemName":"Treatment in someone with HIV","depth":3,"htmlHeader":"<!-- begin field e8187e7d-675e-4302-86ba-a75100d6b8f8 --><h3>How should I treat recurrent genital herpes in someone with HIV?</h3><!-- end field e8187e7d-675e-4302-86ba-a75100d6b8f8 -->","summary":null,"htmlStringContent":"<!-- begin item c8cebb73-006f-4452-884a-a75100d6b998 --><!-- begin field 71bece05-ad39-44c1-8dff-a75100d6b8f8 --><ul><li>People with HIV and recurrent genital herpes can be treated in primary care provided that the infection is uncomplicated and not severe. People with complex and severe infections should be referred to their secondary care specialist for assessment and treatment. <ul><li>Once an uncomplicated episode of genital herpes has resolved, refer the person to a specialist to optimize their antiretroviral treatment.</li></ul></li><li>Self-care measures may be helpful for some people. For more information see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#self-care-measures\">self care</a>.</li><li>If self-care measures are not controlling symptoms, management decisions should be made in partnership with the person. Options include:<ul><li><strong>Episodic antiviral treatment </strong>if attacks are infrequent (less than six attacks per year) — provided there is no immune failure, the treatment for people with HIV with recurrent genital herpes is the same as people without HIV.<ul><li>Prescribe oral aciclovir 200 mg five times a day (or 400 mg three times a day), valaciclovir 500 mg twice a day, or famciclovir 125–500 mg twice a day for 5 days. </li><li>In advanced disease, new lesions may continue to develop at the end of 5 days — it may be necessary to double the dose, or continue beyond 5 days.</li><li>Shorter courses of therapy may be adequate in those with higher CD4 counts (greater than 500 cells/mL).</li></ul></li><li><strong>Suppressive antiviral treatment</strong> if attacks are frequent (six or more attacks per year), causing psychological distress, or affecting the person's social or sex life: <ul><li>Prescribe oral aciclovir 400 mg twice to three times a day, or valaciclovir 500 mg twice a day.</li><li>The dose can be doubled if infection is not controlled.</li><li>If control is still not achieved, consider prescribing oral famciclovir 500 mg twice a day.</li></ul></li></ul></li></ul><!-- end field 71bece05-ad39-44c1-8dff-a75100d6b8f8 --><!-- end item c8cebb73-006f-4452-884a-a75100d6b998 -->","subChapters":[{"id":"4567a8b8-5190-5ec7-b359-ea80bde623b9","slug":"basis-for-recommendation-749","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d6694030-6f22-49ef-9505-a75100d6b8fc --><h4>Basis for recommendation</h4><!-- end field d6694030-6f22-49ef-9505-a75100d6b8fc -->","summary":null,"htmlStringContent":"<!-- begin item 7493b4e9-19d3-460c-900c-a75100d6b8fc --><!-- begin field b6619bcf-2180-4404-8a23-a75100d6b8fc --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of genital herpes </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]<em> </em>and the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>]<em>, </em>and the Summary of Product Characteristics (SPC) for famciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">ABPI, 2016</a>]<em>.</em></p><h5>Dose of antivirals and duration of treatment </h5><ul><li>Be aware that dose recommendations for antivirals and the duration of treatment may differ between guidelines for treatment of genital herpes, the Summary of Product Characteristics and the British National Formulary (BNF). <ul style=\"margin-left: 40px;\"><li>The WHO recommends a famciclovir dose of 500 mg twice a day for episodic treatment of recurrence in people with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>].  </li><li>The SPC for famciclovir recommends a dose of 500 mg twice a day for 7 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">ABPI, 2016</a>].</li><li>However, BASHH considers that standard doses (125 mg twice a day) is sufficient for people with HIV in the absence of immune failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]. </li></ul></li><li>CKS recommends that clinical judgement should be used in determining the dose of antivirals, and duration of treatment.  </li></ul><!-- end field b6619bcf-2180-4404-8a23-a75100d6b8fc --><!-- end item 7493b4e9-19d3-460c-900c-a75100d6b8fc -->","subChapters":[]}]},{"id":"b2da9f20-d9e1-5262-8b77-57029cccdfb9","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 117fee90-61d5-4f84-abb8-a75100d6d3fc --><h3>What advice should I give a person with recurrent genital herpes?</h3><!-- end field 117fee90-61d5-4f84-abb8-a75100d6d3fc -->","summary":null,"htmlStringContent":"<!-- begin item ee8e691f-ab2c-487e-9c24-a75100d6d535 --><!-- begin field 1354ed03-c161-4f52-b124-a75100d6d3fc --><ul><li>Provide a written and verbal explanation of genital herpes simplex: the cause, signs and symptoms, transmission, complications, treatments and the prognosis, for example the Family Planning Association leaflet <a href=\"http://www.fpa.org.uk/sites/default/files/genital-herpes-information-and-advice.pdf\" data-hyperlink-id=\"c89f851a-6d3f-41dc-897b-a98f017bdd83\">Genital herpes</a>.</li><li>Explain that: <ul><li>There is no cure for genital herpes at present.<ul><li>On average, people have 4–5 attacks of genital herpes a year after the first episode. </li><li>Episodes usually last between 5–10 days.</li><li>However, symptoms improve (reduce in frequency and severity) with time and can be well controlled.</li></ul></li><li>Transmission can occur when there are no symptoms (asymptomatic shedding), but the risk is higher when symptomatic. Advise the person:<ul><li>To avoid sexual intercourse (including oro-genital sex) if lesions are present.</li><li>That when used consistently and correctly, male condoms may reduce the risk of transmission.</li><li>Transmission is still possible with close skin contact, or contact with infected secretions during foreplay.</li><li>To avoid sharing towels and flannels with household members, as although it is very unlikely that the virus will be transmitted this way, it is a sensible precaution.</li></ul></li></ul></li><li>Advise people who are concerned about transmitting genital herpes to long-term partners, that:<ul><li>Partners may already be infected even if they do not have symptoms, and should seek advice from a specialist in genito-urinary medicine for screening.</li><li>Suppressive treatment may reduce the risk of transmission to uninfected partners, but specialist advice is needed.</li></ul></li><li>Reinforce the fact that transmission can occur when there are no symptoms (asymptomatic shedding), but that the risk is higher when symptomatic. Advise the person to:<ul><li>Avoid sex (including oro-genital sex) if lesions are present.</li><li>Use condoms with new or uninfected partners.</li><li>Explain that condoms cannot completely prevent transmission, due to close skin contact or contact with infected secretions during foreplay.</li></ul></li><li>Reassure that genital herpes is not hereditary, nor does it increase the risk of cervical cancer or infertility.<ul><li>However, genital herpes can affect pregnancy, and women should inform a healthcare professional if they become pregnant.</li></ul></li><li>Explain that further support is available from the Herpes Viruses Association's helpline 0845 123 2305 (weekdays) or <a href=\"https://herpes.org.uk/\" data-hyperlink-id=\"ec16e34a-c91f-4a13-8b52-a98f017bddb3\">website</a> if required. </li></ul><!-- end field 1354ed03-c161-4f52-b124-a75100d6d3fc --><!-- end item ee8e691f-ab2c-487e-9c24-a75100d6d535 -->","subChapters":[{"id":"465aa6a2-f636-5ce5-90df-f3b53b277946","slug":"basis-for-recommendation-d54","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5c7bd1d3-f4ea-4d3b-a895-a75100d6d401 --><h4>Basis for recommendation</h4><!-- end field 5c7bd1d3-f4ea-4d3b-a895-a75100d6d401 -->","summary":null,"htmlStringContent":"<!-- begin item d540e217-55fa-42c0-a344-a75100d6d401 --><!-- begin field 1e6fdf55-c5db-4429-bb5d-a75100d6d401 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].</p><!-- end field 1e6fdf55-c5db-4429-bb5d-a75100d6d401 --><!-- end item d540e217-55fa-42c0-a344-a75100d6d401 -->","subChapters":[]}]},{"id":"c9d2c8ad-b9de-589c-b3cf-b6dcc038433e","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 3964c85b-9064-4a4d-9d71-a75100d6f5b5 --><h3>When should I refer someone with recurrent genital herpes?</h3><!-- end field 3964c85b-9064-4a4d-9d71-a75100d6f5b5 -->","summary":null,"htmlStringContent":"<!-- begin item b8110b3b-cf4c-45c4-8f9d-a75100d6f67b --><!-- begin field b2a57720-adea-4042-a6ce-a75100d6f5b5 --><ul><li>Consider referring people:<ul><li>Who have breakthrough genital herpes episodes on suppressive treatment.</li><li>For advice on suppressive treatment, if they are concerned about transmitting the herpes simplex virus to long-term partners who are not infected.</li></ul></li></ul><!-- end field b2a57720-adea-4042-a6ce-a75100d6f5b5 --><!-- end item b8110b3b-cf4c-45c4-8f9d-a75100d6f67b -->","subChapters":[{"id":"ebc0f570-2123-5633-a655-d900c1e9bdc4","slug":"basis-for-recommendation-829","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d826d090-acdf-4923-883d-a75100d6f5b9 --><h4>Basis for recommendation</h4><!-- end field d826d090-acdf-4923-883d-a75100d6f5b9 -->","summary":null,"htmlStringContent":"<!-- begin item 829b913e-ea9c-4be7-b831-a75100d6f5b9 --><!-- begin field b0eb49a8-f845-4d74-abf5-a75100d6f5b9 --><p>CKS identified no national referral guidelines for recurrent genital herpes. In the absence of established policy, these recommendations are based on pragmatism, and good clinical practice.</p><ul><li>The British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of genital herpes </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]<em> </em>suggests that in people who are having breakthrough episodes whilst on suppressive antiviral medication, the daily dose of medication may be increased to control symptoms and reduce further attacks.<ul><li>However, the guideline is unclear how long the increased dose should be continued, what follow up is required, and when referral to a specialist is appropriate.</li><li>Due to the lack of clarity in the guideline, CKS recommends seeking specialist advice if necessary, based on clinical experience.</li></ul></li></ul><!-- end field b0eb49a8-f845-4d74-abf5-a75100d6f5b9 --><!-- end item 829b913e-ea9c-4be7-b831-a75100d6f5b9 -->","subChapters":[]}]},{"id":"c3dafb0d-6ac0-564f-a43f-3a96dffa6672","slug":"suspected-sexual-abuse","fullItemName":"Suspected sexual abuse","depth":3,"htmlHeader":"<!-- begin field 4acfa064-df39-42e5-8a46-a75100d72668 --><h3>When should I suspect sexual abuse of a young person?</h3><!-- end field 4acfa064-df39-42e5-8a46-a75100d72668 -->","summary":null,"htmlStringContent":"<!-- begin item 2a362878-aa85-44ac-9227-a75100d726ce --><!-- begin field 774fe88c-25c5-4f94-9b4d-a75100d72668 --><ul><li>For information on when to suspect sexual abuse in a young person with recurrent genital herpes simplex, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#suspected-sexual-abuse\">Suspecting sexual abuse of a young person</a>.</li></ul><!-- end field 774fe88c-25c5-4f94-9b4d-a75100d72668 --><!-- end item 2a362878-aa85-44ac-9227-a75100d726ce -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}